Market Currents
Questcor's (QCOR -38.5%) weakness a buying opportunity , says Leerink Swann. The firm says it's...
-
Wednesday, September 19, 2012, 12:35 PM ETQuestcor's (QCOR -38.5%) weakness a buying opportunity , says Leerink Swann. The firm says it's confirmed with Aetna (AET -0.3%) that Acthar is reimbursed as a second tier drug, and Acthar sales are still seeing more prescriptions written.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
This news story has 4 comments:
Eiso
"Currently, the Company does not believe that the bulletin represents a material change in insurance coverage for Acthar by Aetna. During 2012, Aetna has accounted for approximately 5% of the Company's shipped prescriptions for Acthar. Based on its current assessment of the Clinical Policy Bulletin, the Company does not believe that the bulletin will have a material impact on the Company's results of operations."